SCHEMBL344825

SCHEMBL344825

[O]Cc1cccnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6241871 0.81
SCHEMBL3079246 0.79 CYP1A2 (0.47)
SCHEMBL3076036 0.79 CYP1A2 (0.47)
SCHEMBL7717142 0.78 CYP1A2 (0.43)
SCHEMBL8705523 0.75
SCHEMBL240861 0.75
SCHEMBL1325916 0.75
SCHEMBL238156 0.75
SCHEMBL2343910 0.75
SCHEMBL3295169 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112898286-A Benzothiophene compound or pharmaceutically acceptable salt and isomer thereof, and preparation method, pharmaceutical composition and application thereof 中国药科大学 2021-06-04 CN claimed
CN-107344940-B BTK inhibitors and uses thereof 广东东阳光药业有限公司 2020-04-21 CN claimed
CN-107344940-A BTK inhibitor and application thereof 广东东阳光药业有限公司 2017-11-14 CN claimed
EP-1467976-B1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2011-11-23 EP claimed
WO-2011081310-A3 PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME 한국기초과학지원연구원 (KR) 2011-10-27 WO claimed
JP-2011524881-A 2011-09-08 JP claimed
CN-102123991-A 2-arylaminoquinazolines for the treatment of proliferative diseases NOVARTIS AG 2011-07-13 CN claimed
EP-2307385-A1 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES Novartis AG (CH) 2011-04-13 EP claimed
WO-2010132615-A1 HYDRAZONE COMPOUNDS AND THEIR USE STEIN PHILIP (US) 2010-11-18 WO claimed
US-20100121052-A1 Novel compounds for treating proliferative diseases JAIN RAMA 2010-05-13 US claimed
US-20060025423-A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2006-02-02 US claimed
EP-1458715-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2005-12-07 EP claimed
US-20050075346-A1 Novel compounds ASTRAZENECA AB (SE) 2005-04-07 US claimed
EP-1467976-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2004-10-20 EP claimed
EP-1458715-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-09-22 EP claimed
WO-2003059893-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-07-24 WO claimed
WO-2003051870-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-06-26 WO claimed
EP-0805802-B1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LTD (GB) 2000-08-16 EP claimed
EP-0805802-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE-POULENC RORER LIMITED (GB) 1997-11-12 EP claimed
WO-1996022978-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LIMITED (GB) 1996-08-01 WO claimed